OTC · Healthcare
Marpai, Inc. (MRAI)
As-reported financials and recent SEC filings for Marpai, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$18.1M
Net income
$-16.6M
Net margin
-91.5%
Diluted EPS
$-0.95
ROE
50.9%
P/E (TTM)
—
Market cap
—
Debt / equity
-0.4×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $18.1M | $28.2M | $37.2M | $24.3M | $14.2M |
| Gross profit | — | — | — | — | — |
| Operating income | $-13.6M | $-22.1M | $-28.0M | $-27.0M | $-15.9M |
| Net income | $-16.6M | $-22.1M | $-28.8M | $-26.5M | $-16.0M |
| Diluted EPS | $-0.95 | $-1.92 | $-4.14 | $-5.23 | $-3.18 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-05-22
View on EDGAR →Largest Healthcare peers
Go deeper on MRAI
Search Marpai, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.